Upregulation of FLT1 activates the TGF-β1/Smad3 pathway to promote iodide resistance in thyroid cancer
Cancer Treatment and Research Communications · 2025
DOI: 10.1016/j.ctarc.2025.100991 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2025. Verfasst von Jing Zhuang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, 313000, China; Huzhou Central Ho…. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Smad3 Protein, Transforming Growth Factor beta1, Vascular Endothelial Growth Factor Receptor-1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Huzhou Municipal Science and Technology Bureau.
Abstract (Originalsprache)
BACKGROUND: The identification of new therapeutic targets for patients with radioiodide resistance differentiated thyroid cancer (DTC) may help improve the prognosis for I131-resistant DTC patients. OBJECTIVES: To investigate the potential molecular mechanism of FLT-1 in DTC. METHODS: RNA sequencing data for thyroid cancer in the Cancer Genome. The genes of the tumor samples subjected to I131 radiotherapy were analyzed using the edgeR package. An FLT1-overexpressing plasmid was constructed and a lentivirus was transfected into BHT101 cells. The proliferation, migration, colony formation, invasion and apoptosis were detected by CCK-8 assay, plate cloning, Transwell assay and flow cytometry, respectively. The protein expression of FLT1, NIS, TGF-β1, Smad3, and P-Smad3 was detected using WB. The localization of FOXP3, TGFβ-R1, and p-Smad3 in BHT101 cells was determined with immunofluorescence. A model of subcutaneous tumor formation in BALB/C mice was established to observe the effect of FLT1 on tumor growth. RESULTS: The expression of FLT1 was increased in thyroid cancer cells not treated with I131. The proliferation, colony formation, migration and invasion of FLT1-overexpressing BHT101 cells were significantly increased. The protein expression of TGFβ1 and p-Smad3 in FLT1-overexpressing thyroid cancer cells was significantly increased, while SMAD3 was not significantly changed. The expression of NIS decreased due to the upregulation of FLT1. FOXP3, TGF-βR1, and p-Smad3 were colocalized in FLT1-overexpressing BHT101 cells. In vivo, tumor volume and tumor weight increased with increasing FLT1 expression. CONCLUSION: The upregulation of FLT1 can activate the TGF-β1/Smad3 pathway, downregulate the expression of NIS and enhance the function of thyroid cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, 313000, China; Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejian…
- School of Medicine, Huzhou University, Huzhou, Zhejiang, 313000, China.
- School of Medicine, Huzhou University, Huzhou, Zhejiang, 313000, China. Electronic address: sh908@zjhu.edu.cn.
Förderung
- Huzhou Municipal Science and Technology Bureau
Zitieren
APA
Zhuang, J., Huang, B., Li, J., Wang, Y., Xu, Y., Yu, X., Shen, H., & Gao, W. (2025). Upregulation of FLT1 activates the TGF-β1/Smad3 pathway to promote iodide resistance in thyroid cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2025.100991
Vancouver
Zhuang J, Huang B, Li J, Wang Y, Xu Y, Yu X, et al. Upregulation of FLT1 activates the TGF-β1/Smad3 pathway to promote iodide resistance in thyroid cancer. Cancer Treatment and Research Communications. 2025. doi:10.1016/j.ctarc.2025.100991
BibTeX
@article{Zhuang2025,
author = {Zhuang, Jing and Huang, Bo and Li, Jinyou and Wang, Yingchen and Xu, Yating and Yu, Xiaojian and Shen, Hong and Gao, Weili},
title = {Upregulation of FLT1 activates the TGF-β1/Smad3 pathway to promote iodide resistance in thyroid cancer},
journal = {Cancer Treatment and Research Communications},
year = {2025},
doi = {10.1016/j.ctarc.2025.100991}
}
EUVIMED